A review of dose escalation for FDA-approved products treating solid tumors and hematological malignancies in first-in-human trials
Clinical and Translational Oncology · 2024
DOI: 10.1007/s12094-024-03451-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Translational Oncology, 2024. Verfasst von Zehui Jiang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Gobroad Healthcare Group, 20 Lize Road, Beijing, 100073, China. Hauptthemen laut MEDLINE: Maximum Tolerated Dose, United States Food and Drug Administration, Hematologic Neoplasms, Drug Approval. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gobroad Healthcare Group, 20 Lize Road, Beijing, 100073, China.
- Gobroad Healthcare Group, 20 Lize Road, Beijing, 100073, China. rui.yang@gobroadaro.com.
Zitieren
APA
Jiang, Z., Sun, W., Du, R., & Yang, R. (2024). A review of dose escalation for FDA-approved products treating solid tumors and hematological malignancies in first-in-human trials. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-024-03451-2
Vancouver
Jiang Z, Sun W, Du R, Yang R. A review of dose escalation for FDA-approved products treating solid tumors and hematological malignancies in first-in-human trials. Clinical and Translational Oncology. 2024. doi:10.1007/s12094-024-03451-2
BibTeX
@article{Jiang2024,
author = {Jiang, Zehui and Sun, Wenxuan and Du, Rui and Yang, Rui},
title = {A review of dose escalation for FDA-approved products treating solid tumors and hematological malignancies in first-in-human trials},
journal = {Clinical and Translational Oncology},
year = {2024},
doi = {10.1007/s12094-024-03451-2}
}
EUVIMED